IBDEI3IN ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,1694,0)
;;=SUBSEQUENT OBSERVATION CARE^10^152
;;^UTILITY(U,$J,358.4,1695,0)
;;=OBSERVATION CARE D/C SERVICES^11^152
;;^UTILITY(U,$J,358.4,1696,0)
;;=PROLONGED SERVICES^5^153
;;^UTILITY(U,$J,358.4,1697,0)
;;=VENOUS^6^153
;;^UTILITY(U,$J,358.4,1698,0)
;;=BP MONITORING^1^153
;;^UTILITY(U,$J,358.4,1699,0)
;;=MEDICATION^4^153
;;^UTILITY(U,$J,358.4,1700,0)
;;=CARDIOVASCULAR^2^153
;;^UTILITY(U,$J,358.4,1701,0)
;;=CATHETER^3^153
;;^UTILITY(U,$J,358.4,1702,0)
;;=HEMODIALYSIS-ESRD^13^154
;;^UTILITY(U,$J,358.4,1703,0)
;;=PERITONEAL DIALYSIS ENCOUNTER^22^154
;;^UTILITY(U,$J,358.4,1704,0)
;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^154
;;^UTILITY(U,$J,358.4,1705,0)
;;=COMPLICATIONS/OTHER^4^154
;;^UTILITY(U,$J,358.4,1706,0)
;;=CYSTIC KIDNEY DISEASE^5^154
;;^UTILITY(U,$J,358.4,1707,0)
;;=DIABETES/DIABETIC RENAL DISEASE^6^154
;;^UTILITY(U,$J,358.4,1708,0)
;;=FLUID/ELECTROLYTE DISORDER^7^154
;;^UTILITY(U,$J,358.4,1709,0)
;;=GENERAL SYMPTOMS^8^154
;;^UTILITY(U,$J,358.4,1710,0)
;;=GENITAL/URINARY^9^154
;;^UTILITY(U,$J,358.4,1711,0)
;;=HEMATOLOGY^11^154
;;^UTILITY(U,$J,358.4,1712,0)
;;=HYPERTENSION^14^154
;;^UTILITY(U,$J,358.4,1713,0)
;;=INFECTIOUS DISEASE^15^154
;;^UTILITY(U,$J,358.4,1714,0)
;;=NEPHRITIS GLUMERULONEPHRITIS^17^154
;;^UTILITY(U,$J,358.4,1715,0)
;;=NEPHRITIS INTERSTITIAL^18^154
;;^UTILITY(U,$J,358.4,1716,0)
;;=NEPHROTIC SYNDROME^20^154
;;^UTILITY(U,$J,358.4,1717,0)
;;=OBSTRUCTIVE UROPATHY^21^154
;;^UTILITY(U,$J,358.4,1718,0)
;;=TRANSPLANT^24^154
;;^UTILITY(U,$J,358.4,1719,0)
;;=CKD/KIDNEY DISEASE^3^154
;;^UTILITY(U,$J,358.4,1720,0)
;;=HEMODIALYSIS-AKI^12^154
;;^UTILITY(U,$J,358.4,1721,0)
;;=ACUTE KIDNEY INJURY^1^154
;;^UTILITY(U,$J,358.4,1722,0)
;;=GLOMERULAR DISEASE^10^154
;;^UTILITY(U,$J,358.4,1723,0)
;;=KIDNEY INVOLVMNT IN SYSTEMIC DISEASE^16^154
;;^UTILITY(U,$J,358.4,1724,0)
;;=NEPHROLITHASIS^19^154
;;^UTILITY(U,$J,358.4,1725,0)
;;=POISONING & INTOXICATIONS^23^154
;;^UTILITY(U,$J,358.4,1726,0)
;;=ESTABLISHED PATIENT^1^155
;;^UTILITY(U,$J,358.4,1727,0)
;;=CONSULTATIONS/OPINIONS^2^155
;;^UTILITY(U,$J,358.4,1728,0)
;;=NEW PATIENTS^3^155
;;^UTILITY(U,$J,358.4,1729,0)
;;=NEUROLOGY/SEIZURE^7^156
;;^UTILITY(U,$J,358.4,1730,0)
;;=EEG^4^156
;;^UTILITY(U,$J,358.4,1731,0)
;;=SLEEP TESTING^9^156
;;^UTILITY(U,$J,358.4,1732,0)
;;=MUSCLE TESTING/EMG^6^156
;;^UTILITY(U,$J,358.4,1733,0)
;;=EVOKED POTENTIAL^5^156
;;^UTILITY(U,$J,358.4,1734,0)
;;=BIOPSY^2^156
;;^UTILITY(U,$J,358.4,1735,0)
;;=AUTONOMIC FUNCTION TESTS^1^156
;;^UTILITY(U,$J,358.4,1736,0)
;;=STEREOTACTIC^10^156
;;^UTILITY(U,$J,358.4,1737,0)
;;=EDUCATION^3^156
;;^UTILITY(U,$J,358.4,1738,0)
;;=NEUROSTIMULATORS^8^156
;;^UTILITY(U,$J,358.4,1739,0)
;;=SEIZURES/EPILEPSY/SPELLS^14^157
;;^UTILITY(U,$J,358.4,1740,0)
;;=CEREBROVASCULAR DISEASE^2^157
;;^UTILITY(U,$J,358.4,1741,0)
;;=DIZZINESS^3^157
;;^UTILITY(U,$J,358.4,1742,0)
;;=ENCEPHALOPATHY^5^157
;;^UTILITY(U,$J,358.4,1743,0)
;;=HEADACHE^6^157
;;^UTILITY(U,$J,358.4,1744,0)
;;=MOVEMENT DISORDERS^8^157
;;^UTILITY(U,$J,358.4,1745,0)
;;=NEOPLASMS^9^157
;;^UTILITY(U,$J,358.4,1746,0)
;;=NEURODEGENERATIVE DISEASE^10^157
;;^UTILITY(U,$J,358.4,1747,0)
;;=OTHER^12^157
;;^UTILITY(U,$J,358.4,1748,0)
;;=CARDIAC DISORDERS^1^157
;;^UTILITY(U,$J,358.4,1749,0)
;;=INFLAMMATORY & DEMYELINATING DISEASES^7^157
;;^UTILITY(U,$J,358.4,1750,0)
;;=NEUROMUSCULAR DISORDERS^11^157
;;^UTILITY(U,$J,358.4,1751,0)
;;=PAIN^13^157
;;^UTILITY(U,$J,358.4,1752,0)
;;=SPINAL CONDITIONS^15^157
;;^UTILITY(U,$J,358.4,1753,0)
;;=SYMPTOMS^16^157
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3IN 3962 printed Dec 13, 2024@02:49:31 Page 2
IBDEI3IN ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,1694,0)
+2 ;;=SUBSEQUENT OBSERVATION CARE^10^152
+3 ;;^UTILITY(U,$J,358.4,1695,0)
+4 ;;=OBSERVATION CARE D/C SERVICES^11^152
+5 ;;^UTILITY(U,$J,358.4,1696,0)
+6 ;;=PROLONGED SERVICES^5^153
+7 ;;^UTILITY(U,$J,358.4,1697,0)
+8 ;;=VENOUS^6^153
+9 ;;^UTILITY(U,$J,358.4,1698,0)
+10 ;;=BP MONITORING^1^153
+11 ;;^UTILITY(U,$J,358.4,1699,0)
+12 ;;=MEDICATION^4^153
+13 ;;^UTILITY(U,$J,358.4,1700,0)
+14 ;;=CARDIOVASCULAR^2^153
+15 ;;^UTILITY(U,$J,358.4,1701,0)
+16 ;;=CATHETER^3^153
+17 ;;^UTILITY(U,$J,358.4,1702,0)
+18 ;;=HEMODIALYSIS-ESRD^13^154
+19 ;;^UTILITY(U,$J,358.4,1703,0)
+20 ;;=PERITONEAL DIALYSIS ENCOUNTER^22^154
+21 ;;^UTILITY(U,$J,358.4,1704,0)
+22 ;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^154
+23 ;;^UTILITY(U,$J,358.4,1705,0)
+24 ;;=COMPLICATIONS/OTHER^4^154
+25 ;;^UTILITY(U,$J,358.4,1706,0)
+26 ;;=CYSTIC KIDNEY DISEASE^5^154
+27 ;;^UTILITY(U,$J,358.4,1707,0)
+28 ;;=DIABETES/DIABETIC RENAL DISEASE^6^154
+29 ;;^UTILITY(U,$J,358.4,1708,0)
+30 ;;=FLUID/ELECTROLYTE DISORDER^7^154
+31 ;;^UTILITY(U,$J,358.4,1709,0)
+32 ;;=GENERAL SYMPTOMS^8^154
+33 ;;^UTILITY(U,$J,358.4,1710,0)
+34 ;;=GENITAL/URINARY^9^154
+35 ;;^UTILITY(U,$J,358.4,1711,0)
+36 ;;=HEMATOLOGY^11^154
+37 ;;^UTILITY(U,$J,358.4,1712,0)
+38 ;;=HYPERTENSION^14^154
+39 ;;^UTILITY(U,$J,358.4,1713,0)
+40 ;;=INFECTIOUS DISEASE^15^154
+41 ;;^UTILITY(U,$J,358.4,1714,0)
+42 ;;=NEPHRITIS GLUMERULONEPHRITIS^17^154
+43 ;;^UTILITY(U,$J,358.4,1715,0)
+44 ;;=NEPHRITIS INTERSTITIAL^18^154
+45 ;;^UTILITY(U,$J,358.4,1716,0)
+46 ;;=NEPHROTIC SYNDROME^20^154
+47 ;;^UTILITY(U,$J,358.4,1717,0)
+48 ;;=OBSTRUCTIVE UROPATHY^21^154
+49 ;;^UTILITY(U,$J,358.4,1718,0)
+50 ;;=TRANSPLANT^24^154
+51 ;;^UTILITY(U,$J,358.4,1719,0)
+52 ;;=CKD/KIDNEY DISEASE^3^154
+53 ;;^UTILITY(U,$J,358.4,1720,0)
+54 ;;=HEMODIALYSIS-AKI^12^154
+55 ;;^UTILITY(U,$J,358.4,1721,0)
+56 ;;=ACUTE KIDNEY INJURY^1^154
+57 ;;^UTILITY(U,$J,358.4,1722,0)
+58 ;;=GLOMERULAR DISEASE^10^154
+59 ;;^UTILITY(U,$J,358.4,1723,0)
+60 ;;=KIDNEY INVOLVMNT IN SYSTEMIC DISEASE^16^154
+61 ;;^UTILITY(U,$J,358.4,1724,0)
+62 ;;=NEPHROLITHASIS^19^154
+63 ;;^UTILITY(U,$J,358.4,1725,0)
+64 ;;=POISONING & INTOXICATIONS^23^154
+65 ;;^UTILITY(U,$J,358.4,1726,0)
+66 ;;=ESTABLISHED PATIENT^1^155
+67 ;;^UTILITY(U,$J,358.4,1727,0)
+68 ;;=CONSULTATIONS/OPINIONS^2^155
+69 ;;^UTILITY(U,$J,358.4,1728,0)
+70 ;;=NEW PATIENTS^3^155
+71 ;;^UTILITY(U,$J,358.4,1729,0)
+72 ;;=NEUROLOGY/SEIZURE^7^156
+73 ;;^UTILITY(U,$J,358.4,1730,0)
+74 ;;=EEG^4^156
+75 ;;^UTILITY(U,$J,358.4,1731,0)
+76 ;;=SLEEP TESTING^9^156
+77 ;;^UTILITY(U,$J,358.4,1732,0)
+78 ;;=MUSCLE TESTING/EMG^6^156
+79 ;;^UTILITY(U,$J,358.4,1733,0)
+80 ;;=EVOKED POTENTIAL^5^156
+81 ;;^UTILITY(U,$J,358.4,1734,0)
+82 ;;=BIOPSY^2^156
+83 ;;^UTILITY(U,$J,358.4,1735,0)
+84 ;;=AUTONOMIC FUNCTION TESTS^1^156
+85 ;;^UTILITY(U,$J,358.4,1736,0)
+86 ;;=STEREOTACTIC^10^156
+87 ;;^UTILITY(U,$J,358.4,1737,0)
+88 ;;=EDUCATION^3^156
+89 ;;^UTILITY(U,$J,358.4,1738,0)
+90 ;;=NEUROSTIMULATORS^8^156
+91 ;;^UTILITY(U,$J,358.4,1739,0)
+92 ;;=SEIZURES/EPILEPSY/SPELLS^14^157
+93 ;;^UTILITY(U,$J,358.4,1740,0)
+94 ;;=CEREBROVASCULAR DISEASE^2^157
+95 ;;^UTILITY(U,$J,358.4,1741,0)
+96 ;;=DIZZINESS^3^157
+97 ;;^UTILITY(U,$J,358.4,1742,0)
+98 ;;=ENCEPHALOPATHY^5^157
+99 ;;^UTILITY(U,$J,358.4,1743,0)
+100 ;;=HEADACHE^6^157
+101 ;;^UTILITY(U,$J,358.4,1744,0)
+102 ;;=MOVEMENT DISORDERS^8^157
+103 ;;^UTILITY(U,$J,358.4,1745,0)
+104 ;;=NEOPLASMS^9^157
+105 ;;^UTILITY(U,$J,358.4,1746,0)
+106 ;;=NEURODEGENERATIVE DISEASE^10^157
+107 ;;^UTILITY(U,$J,358.4,1747,0)
+108 ;;=OTHER^12^157
+109 ;;^UTILITY(U,$J,358.4,1748,0)
+110 ;;=CARDIAC DISORDERS^1^157
+111 ;;^UTILITY(U,$J,358.4,1749,0)
+112 ;;=INFLAMMATORY & DEMYELINATING DISEASES^7^157
+113 ;;^UTILITY(U,$J,358.4,1750,0)
+114 ;;=NEUROMUSCULAR DISORDERS^11^157
+115 ;;^UTILITY(U,$J,358.4,1751,0)
+116 ;;=PAIN^13^157
+117 ;;^UTILITY(U,$J,358.4,1752,0)
+118 ;;=SPINAL CONDITIONS^15^157
+119 ;;^UTILITY(U,$J,358.4,1753,0)
+120 ;;=SYMPTOMS^16^157
